Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.

Front Oncol · 2022 · PMC9157648 · PMID 35664762

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Within the first hours of treatment, trastuzumab alone slightly reduced cell migration, whereas pertuzumab showed a trend toward a reduction ( Figure 4A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.